{"slug":"chonluten","seoKey":"chonluten","displayName":"Chonluten","codes":["T-34","EDG"],"synonyms":["Glu-Asp-Gly","EDG","EDG tripeptide","H-Glu-Asp-Gly-OH","T-34 tripeptide","L-glutamyl-L-aspartyl-glycine","glutamyl-aspartyl-glycine (the NLM MeSH supplementary concept heading and the PubChem title)","Glycine, N-(N-L-alpha-glutamyl-L-alpha-aspartyl)-","Khonluten / Хонлутен (Russian trade name)","AC-7 / АС-7 (the peptide complex declared for the Russian oral products, not the injected substance)"],"legalClass":"research_chemical","identifiers":{"cas":"75007-24-8","pubchemCid":194641,"inchikey":"DSPQRJXOIXHOHK-WDSKDSINSA-N","wikidataQid":"Q82988318","formula":"C11H17N3O8","molecularWeight":319.27,"sequence":"Glu-Asp-Gly"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not registered as a substance. Five federal queries returned no match on 2026-09-15: no drug label, no adverse event report, no entry in the labelling database with its stated data cut-off of 2026-09-14, and no record in the substance registration system, which is why there is no unique ingredient identifier. Control queries on each of those interfaces returned results for an approved medicine, so the negative findings are verified rather than interface failures. The substance also appears in none of the three categories of the list of bulk substances nominated for pharmacy compounding, whose full text was downloaded and searched; it was never even nominated for review. Distribution in the United States runs through the research-chemical channel with an explicit research-use-only and not-for-human-consumption label, and no marketing as a dietary supplement was found.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22chonluten%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report, no withdrawal document and no pharmacopoeial monograph. The register itself could not be queried on 2026-09-15: the search page answered with an authorisation error and, on direct request, with a refusal, for the control query as well as for this substance. The negative finding therefore rests on the complete absence of the substance from every other authority database that could be checked and on the absence of any registered clinical trial, not on a primary regulator document. Separately from medicines law, the Russian oral products are food supplements in their own country; importing them does not make them marketable food here, because a meaningful history of consumption in the Union before 15 May 1997 is not documented for either the declared peptide complex or a lung peptide extract, which brings them under the novel food rules.","source":"https://www.ema.europa.eu/en/search?search_api_fulltext=chonluten"},{"market":"DE","status":"not_approved","note":"Neither a national nor a European marketing authorisation exists, so the injected preparation is not a marketable medicinal product, and it is not marketable as a food either. The substance is also not named in the schedule to the anti-doping act: the full text was checked on 2026-09-15 for the trade name, the sequence, the abbreviation and the development code without a hit, and the word tripeptide does not appear in that schedule at all. Its section on peptide hormones, growth factors, related substances and mimetics lists what it covers by name, from erythropoiesis-stimulating substances through growth hormone fragments to releasing hormones and secretagogues, and a tripeptide without hormone action falls under none of those headings; two listed substances were found in the same text as a control. Possession of more than a small quantity is therefore not criminalised by that provision. Sporting rules are unaffected.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register could not be evaluated on 2026-09-15: the search for this substance and a control search for an approved active ingredient returned byte-identical responses of the same size, that is the JavaScript shell of the page without any server-rendered results. This is recorded as an unverified gap rather than as a confirmed negative finding, and it rests on the absence of any entry elsewhere and on the absence of any clinical development.","source":"https://products.mhra.gov.uk/search/?search=chonluten"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-15 for the trade name, the sequence and both amino acid names without a hit, while a control term in the same document was found. There is no generic peptide position in that instrument, and the peptides it does schedule are listed by name, so this is a real absence. Absence of a listing is not a clearance: a substance with a therapeutic purpose that is not listed falls under the rules for unregistered therapeutic goods. The register of therapeutic goods itself could not be queried on that date, the request timing out and a direct attempt breaking off.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database; the query returned an empty result on 2026-09-15, while a control query for an authorised product returned six records with its identification number, so the interface was working and the negative finding is verified.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=chonluten"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. No direct register query was possible on 2026-09-15, the pages addressed answering with a not-found error. Since the substance is held as a medicine in none of the registers checked worldwide and no registered clinical trial exists, a Swiss-only authorisation would be extraordinarily unlikely, but it is not positively ruled out.","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"in_vitro","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/194641","https://www.wikidata.org/wiki/Q82988318"],"lastVerified":"2026-09-15","version":"1.0","published":true,"locale":"en","title":"Chonluten: what the studies show, status and safety","summary":"Chonluten is a synthetic chain of three amino acids from a St Petersburg institute, traded as a lung peptide. Its inventors' own overview table lists it as a stomach and stress peptide and gives the lung role to a different molecule. No experiment on lung or bronchial tissue has ever been done with it, and no trial in people has been registered. The one test in people sits in a patent application rather than in a journal.","updated":"2026-09-15","url":"https://mypep.app/peptides/chonluten"}